Showing 11-20 of 234 results for "".
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with Nielsen BioSciences, Inc. to study the safety and efficacy of Candin for the treatment of common warts. Vial will support Nielsen with their Phase III, randomized, double-blind, placebo-controlled clinical study of Candin for the treatment of Verruca vulgaris in adolescent…
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once daily Ivarmacitinib as mo…
- Expert FDA Panel Recommends Skin Lesion Analyzers and Apps for Skin Cancer Detection Keep Class III Statushttps://practicaldermatology.com/news/expert-fda-panel-recommends-skin-lesion-analyzers-and-apps-for-skin-cancer-detection-keep-class-iii-status/2461293/The FDA held a meeting with the Medical Devices Advisory Committee in late July to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more…
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with no patient withdrawals f…
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follow on the BELMONT study announced last year that sho…
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study, Ye…
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Academy of Dermatology …
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind trials (EV001 and EV002), the composit…
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when administered via cannula for perioral rejuvenation. Restylane® Lyft Hand Rejuvenation Study The pivotal Phase III trial is a randomize…
- Interferon Not Beneficial for Most Stage III Melanomahttps://practicaldermatology.com/news/interferon-not-beneficial-for-most-stage-iii-melanoma/2458703/Most stage III melanoma patients do not benefit from treatment with interferon, according to final results for the Sunbelt Melanoma Trial, published online in the Journal of Clinical Oncology. Interferon was approved by the FDA in 1995 as a therapy for melanoma based on a study of patients with mu…